AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04058132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Structural brain Magnetic Resonance Imaging (MRI
Description: Structural brain Magnetic Resonance Imaging (MRI): The scanner used is a 3.0 Tesla MR (Model 750, General Electric Healthcare), which is equipped with a high-performance gradient subsystem and a 32-channel head coil (General Electric Healthcare). These scans involve lying still in a scanner for several minutes at a time which is tube shaped, using magnetism to take images of the brain. There is no radiation in MRI. The participants will have up to 3 research brain MRIs. Healthy controls will have 1 MRI session.~Common TBI MRI techniques will be performed. Block-design BOLD fMRI during which there will be a 7 minute hypercapnia challenge will be done to assess brain blood flow and measure cerebral vascular reactivity (CVR).
Study NCT01452932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The physiotherapeutic intervention was based on the Kabat (PNF) technique. Thirty-three sessions were planed. Each session lasted between thirty and fifty minutes.~The experimental group was guided by a physiotherapist or a physiotherapy student and each session took place in a hospital auditorium provided with oxygen cylinders, chairs and water.~Each session consisted of a warm up and stretch period, a period of resistance training of the upper limbs with their rest periods in which diaphragmatic breathing exercises and finally a cooling period.~The instructions and instruments given to each participant such as weights and elastic bands were the same for all of them.
Study NCT01452932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Description: The intervention for the other group was the Yoga technique. Thirty-six sessions were planed. Each session was based on breathing, relaxation, and stretching exercises. Each session lasted between thirthy and forty minutes.~The group was led by a Yoga Instructor and each sessions took place in a hospital auditorium provided by oxygen cylinders, chairs and water.~No instruments were needed for this intervention.
Study NCT01039662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arabinose and indigestible dextrin
Study NCT01039662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02657473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tobramycin inhalation solution
Study NCT02657473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9% inhalation solution
Study NCT02609113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strong Magnetic Wristband
Study NCT02609113 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Weaker Magnetic Wristband
Study NCT01213199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: Adapalene Gel 0.3%
Study NCT00913952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions
Study NCT00913952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
Study NCT00913952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
Study NCT00778843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid
Description: Viusid, three oral sachets daily during 24 weeks
Study NCT00778843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three oral sachets daily during 24 weeks
Study NCT03563924 — intervention group
Intervention type: OTHER
Intervention: Setting up a specific care path AlloTC for management of TVE in patients with cancer
Description: Setting up a specific care path AlloTC for management of TVE in patients with cancer with a specific coordination nurse within the AlloTC multidisciplinary team as a privileged interlocutor for health professionals and patients with the aim of simplifying the care pathways and ensuring a hospital-city interface organized in collaboration with the attending physician, to develop and publicize tools available for patients and caregivers (information documents, patient monitoring protocols, etc.)
Study NCT01984658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alecsat
Description: The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
Study NCT01715012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: ST266 is applied daily by spray to burn wound and skin graft donor site
Study NCT01715012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is applied daily by spray to burn wound and skin graft donor site
Study NCT04458090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A decision aid for patients considering Hospice care.
Description: A 12 page booklet and 17 min video describing hospice care
Study NCT00547443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00547443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00547443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV
Study NCT00547443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00547443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00547443 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given 5 days a week for 7.5 weeks
Study NCT00547443 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given 5 days a week for 7.5 weeks
Study NCT03993067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Hemopatch is a collagen based sealant is a hemostat agent. We want to investigate his role in the prevention of post operative biliary fistula
Study NCT03993067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fribrin glue and Tabotamp
Description: Fibrin glue and Tabotampis the standard treatment
Study NCT04183543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Fields
Description: The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.
Study NCT04183543 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Description: Inactive Pulsed Electromagnetic Field therapy
Study NCT02460796 — intervention group
Intervention type: OTHER
Intervention: Hippotherapy
Description: The sessions began with a 5 minutes warm up that involved stretching and body awareness exercises. Then, the training was conducted for 20 minutes with arms and torso exercises, changes of direction called serpentine movements; up and down hip movements with feet on stirrups, and forced expiration. In the final 5 minutes, exercises for relaxation were conducted with the horse which involved moving the hand on the horse's neck, laying forward on the head and stroking the horse. The horses walking speed was between 5.8 and 6.4 Km/h.
Study NCT03357588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified monitoring
Description: Intensified virological monitoring during first-line ART with viral load monitoring at month 6 of ART and 3-monthly thereafter, followed-up consecutively by point-of-care qualitative drug level testing and drug resistance testing in case of a viral load >1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
Study NCT03357588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care monitoring
Description: Standard-of-care virological monitoring during first-line ART as described by WHO and South African National Department of Health ART guidelines, consisting of viral load monitoring at month 6 and 12 of ART and annually thereafter, followed-up by a repeat measurement within 3 months after a viral load >1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
Study NCT00942097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos
Description: CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
Study NCT00942097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos
Description: CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
Study NCT00942097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathy and Nutritional oriented diet
Description: Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
Study NCT00942097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Homeopathy and Nutritional oriented diet
Description: Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
Study NCT00380653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine
Study NCT02917642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Irrigation
Description: Passive Ultrasonic Irrigation is based on the transmission of acoustic energy through the irrigant by a stainless steel wire or endodontic file
Study NCT02917642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Ultrasonic Irrigation
Description: Syringe and needle irrigation with no-ultrasonic activation
Study NCT02812017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thirty Million Words- Well Baby
Description: Through evidence-based strategies, the TMW-WB curriculum teaches parents how to harness the power of their words to build their child's brain and impact their child's learning trajectory.
Study NCT02812017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Safety Starts at Home
Description: A portion of the Safety Stars at Home set is shown. Demonstrating proven childproofing techniques and accident-prevention strategies, which unifies safety guidelines and shows caregivers how to take proactive measures at home. Many no- or low-cost safety alternatives are offered.
Study NCT05295667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler measurement in combination with amniotic fluid volume
Description: Ultrasonographic evaluation
Study NCT03945604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210 + Apatinib +Fluzoparib
Description: SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.
Study NCT02767349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNK-155
Description: 2 or 3 tablets initial dose, followed by two tablets every twelve hours
Study NCT00700388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPEP device (UNIKO)
Description: This technique is mainly based on a continuous low-pressure insufflation in the airways, which is likely to reduce (or even avoid) the potential pressure-related damages of other commonly used devices. This device should be used only in those individuals who are showing a normal competence of their cough reflex, thus it should be considered as a means which may help those techniques normally adopted for the individual's bronchial hygiene.
Study NCT00700388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MABT (Manually assisted breathing techniques)
Description: Conventionally manually assisted breathing techniques
Study NCT04581707 — intervention group
Intervention type: DEVICE
Intervention: Kyphoplasty Single Balloon Catheter Allevo
Description: Vertebral compression fractures treated with Kyphoplasty Single Balloon Catheter Allevo (Joline®) and BonOs® Inject bone cement
Study NCT04581707 — intervention group
Intervention type: DEVICE
Intervention: Quattroplasty Double Balloon Catheter Stop'n GO
Description: Vertebral compression fractures treated with Stop'n GO double balloon kyphoplasty system (Joline®) and BonOs® Inject bone cement
Study NCT02490670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Administered orally
Study NCT02490670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Administered orally
Study NCT02525770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiostereometric analysis (RSA)
Study NCT00552188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-2291
Description: 100 mg, oral dosing, 1 time daily for 24 weeks
Study NCT00552188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dosing, 1 time daily for 24 weeks
Study NCT03867370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab (JS001 )
Description: Given IV
Study NCT03867370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab (JS001 ) Lenvatinib
Description: Given IV 4 mg capsules
Study NCT03867370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab (JS001 ) Lenvatinib
Description: Given IV 4 mg capsules
Study NCT04534816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Perfusion assessments
Study NCT03353337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 months.
Study NCT03353337 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controlled group
Description: General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
Study NCT00732446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Dexamethasone combined
Description: moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
Study NCT00732446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: moxifloxacin 0,5% qid and
Study NCT00732446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 0,1% qid
Study NCT02653417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD1901
Description: RAD1901
Study NCT02653417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04461067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonography
Description: Ultrasonography of the stomach is performed to measure the diameter of the antrum
Study NCT04277923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Description: the lipid of all-in-one is less than 4g/kg.d
Study NCT04277923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipofundin
Description: the lipid of all-in-one is less than 4g/kg.d
Study NCT05033704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% human plasma protein fraction (PPF)
Description: Infusion of 5% human plasma protein fraction PPF. PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium).
Study NCT04160754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention
Description: Individuals assigned to the experimental group will receive interventions normally provided at the clinic and eight 1.5-hour group sessions of MBRP. Each sessions will occur once per week and will target a specific theme such as being aware of personal triggers, maintaining present focus, allowing or letting things be, responding to emotional and physical experiences in skillful ways, and recognizing intrusive thoughts. Each session will incorporate a mindfulness meditation technique (e.g.,SOBER breathing space and urge surfing). Participants will receive materials (e.g., recordings) with which to perform practices and meditation during the intervention phase.
Study NCT04160754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (CTL)
Description: Individuals assigned to the CTL group will receive interventions provided at the clinic and up to eight CTL sessions. The CTL group will receive information (reading) and videos once per week on health behaviors (e.g., exercise, eating) and the neurobiology of addiction. This approach will reduce the possibility that intervention effects are solely due to the experimental group's receiving extra attention. In contrast to the active intervention, sessions will be educational in nature, with no motivational, cognitive, or behavioral components
Study NCT02945709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Attention control training (ACT)
Description: In this intervention, participants will be trained with a personalized Dot-Probe task. Each participant will perform the task with the set of words that he or she ranked as the most threatening according to a Word Ranking Task.
Study NCT02945709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-personalized Attention control training (ACT)
Description: In this intervention, participants will be trained with the same Dot-Probe task as in the personalized condition, except that the word stimuli will be randomly fit for each participant. It should be noted that 25% out of the words in this condition will be high ranked words according to each patient's word ranking. The aim of this is to enhance similarity to a generic ACT intervention (see Badura-Brack et al., 2015), where there is some degree of exposure to what one may consider personalized stimuli (i.e., threat words that were randomly included by the researchers), although it is not deliberately set to idiosyncratic preferences.
Study NCT02945709 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control training.
Description: In this intervention, participants will perform a computerized task, similar to the Dot-Probe task. In each trial, one neutral word will be presented at the center of the screen and participants will respond to a probe ('E' or 'f') presented following the removal of the words display. This version does not include the essential ingredients thought to reduce PTSD symptoms in the other dot-probe tasks: exposure to threat content and competition on attentional resources. Thus, this control version provides a control condition for the ACT interventions.
Study NCT02110043 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)
Study NCT02110043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)
Study NCT02110043 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: training
Description: intensive training of visual-spatial abilities (in LOCATO task)
Study NCT02110043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: intensive training of visual-spatial abilities (in LOCATO task)
Study NCT03041506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml.
Study NCT03041506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided ISCB
Description: Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml.
Study NCT03041506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: IV administration up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 seconds) for sedation and pain relief.
Study NCT03041506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: IV administration up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds) for sedation and pain relief.
Study NCT00942994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren/Amlodipine
Description: Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)
Study NCT00942994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
Description: Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)
Study NCT02583737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: freeze bone allograft
Description: sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.